AUT00206 Added to Care for Schizophrenia: Safety and Brain Measures
About this title
Read the official source — NCT03164876This study evaluated the safety of AUT00206 for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the safety of AUT00206 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Autifony Therapeutics Limited
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT03164876
- Official title
Show the full official title
A Randomised, Double-blind, Placebo-controlled Study of the Safety, Pharmacokinetics and Exploratory Pharmacodynamics of AUT00206 for 28 Days as Adjunctive Therapy in Patients With Recently Diagnosed Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
London
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety of AUT00206 for people with schizophrenia.
Who is behind this study?
The study sponsor is Autifony Therapeutics Limited.
Did this study involve medication?
Yes. The study involved medication, including AUT00206 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
